THERMO FISHER SCIENTIFIC INC.
In the published model solve dated 2026-Q2, anchored at $622.18, THERMO FISHER SCIENTIFIC INC. (TMO) is priced for +23.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• Thermo Fisher is the picks-and-shovels vendor to the entire life-sciences economy, $45.2B of trailing revenue across consumables, instruments, and services, with $4.65B returned to shareholders over the past year and a fresh $9 billion acquisition of Clario extending its clinical-trial data business [Source: company press releases, Q1 2026]. • The risk is the price, not the business: today's level embeds operating-profit growth of roughly 21.6% a year for five years, a pace only about 35% of c
Is TMO overvalued? See what's priced in →
2,524 institutional managers reported holding TMO in 13F filings for the quarter ended 2026-03-31. Together they hold about 88% of the company; the top 10 hold 37%. 126 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 4.4M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TMO has cut its share count 5.3% over the past five years, spending $16.00B on repurchases. It pays a dividend, and has for 14 years running, raised 8 years straight; the current rate is $1.72 a share annually. Cash returned over the past three years: $1.65B in dividends and $10.00B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at TMO over the trailing three years: 2024: 2 buys totaling $11k. 22 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TMO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-05-07 | +6.2% | +1.3% |
| 2022-08-06 | +2.8% | -11.3% |
| 2022-11-05 | -3.2% | +8.0% |
| 2023-02-24 | +2.9% | +2.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TMO's latest 8-K filings: 2026-07-23 (items 2.02, 9.01); 2026-05-26 (items 5.07); 2026-04-23 (items 2.02, 9.01); 2026-03-24 (items 8.01, 9.01); 2026-02-12 (items 1.01, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.